Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective

Michael P. Triebwasser; David M. Barrett; Hamid Bassiri; Nancy Bunin; Caitlin Elgarten; Jason Freedman; Abdallah S. Geera; Dimitri Monos; Michele P. Lambert; Timothy Olson; Alix E. Seif; Michele Paessler; Whitney Petrosa; Anne F. Reilly; Neil Romberg; Kathleen E. Sullivan; Ghazal Z. Quinn; Edward Behrens; David T. Teachey

doi:10.1002/pbc.29026

Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective

Michael P. Triebwasser, David M. Barrett, Hamid Bassiri, Nancy Bunin, Caitlin Elgarten, Jason Freedman, Abdallah S. Geera, Dimitri Monos, Michele P. Lambert, Timothy Olson, Alix E. Seif, Michele Paessler, Whitney Petrosa, Anne F. Reilly, Neil Romberg, Kathleen E. Sullivan, Ghazal Z. Quinn, Edward Behrens, David T. Teachey

Research output: Contribution to journal › Letter › peer-review

15 Scopus citations

Original language	English
Article number	e29026
Journal	Pediatric Blood and Cancer
Volume	68
Issue number	7
DOIs	https://doi.org/10.1002/pbc.29026
State	Published - Jul 2021
Externally published	Yes

Access to Document

10.1002/pbc.29026

Cite this

Triebwasser, M. P., Barrett, D. M., Bassiri, H., Bunin, N., Elgarten, C., Freedman, J., Geera, A. S., Monos, D., Lambert, M. P., Olson, T., Seif, A. E., Paessler, M., Petrosa, W., Reilly, A. F., Romberg, N., Sullivan, K. E., Quinn, G. Z., Behrens, E., & Teachey, D. T. (2021). Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. Pediatric Blood and Cancer, 68(7), Article e29026. https://doi.org/10.1002/pbc.29026

@article{292e69572c1f43c597fc955bf005c853,

title = "Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective",

author = "Triebwasser, {Michael P.} and Barrett, {David M.} and Hamid Bassiri and Nancy Bunin and Caitlin Elgarten and Jason Freedman and Geera, {Abdallah S.} and Dimitri Monos and Lambert, {Michele P.} and Timothy Olson and Seif, {Alix E.} and Michele Paessler and Whitney Petrosa and Reilly, {Anne F.} and Neil Romberg and Sullivan, {Kathleen E.} and Quinn, {Ghazal Z.} and Edward Behrens and Teachey, {David T.}",

note = "Funding Information: This work was supported by the Immune Dysregulation Frontier Program at the Children's Hospital of Philadelphia. This publication was made possible by an NHLBI-funded postdoctoral fellowship to MPT (T32 HL007150). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NHLBI or NIH.",

year = "2021",

month = jul,

doi = "10.1002/pbc.29026",

language = "English",

volume = "68",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "7",

}

Triebwasser, MP, Barrett, DM, Bassiri, H, Bunin, N, Elgarten, C, Freedman, J, Geera, AS, Monos, D, Lambert, MP, Olson, T, Seif, AE, Paessler, M, Petrosa, W, Reilly, AF, Romberg, N, Sullivan, KE, Quinn, GZ, Behrens, E & Teachey, DT 2021, 'Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective', Pediatric Blood and Cancer, vol. 68, no. 7, e29026. https://doi.org/10.1002/pbc.29026

TY - JOUR

T1 - Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective

AU - Triebwasser, Michael P.

AU - Barrett, David M.

AU - Bassiri, Hamid

AU - Bunin, Nancy

AU - Elgarten, Caitlin

AU - Freedman, Jason

AU - Geera, Abdallah S.

AU - Monos, Dimitri

AU - Lambert, Michele P.

AU - Olson, Timothy

AU - Seif, Alix E.

AU - Paessler, Michele

AU - Petrosa, Whitney

AU - Reilly, Anne F.

AU - Romberg, Neil

AU - Sullivan, Kathleen E.

AU - Quinn, Ghazal Z.

AU - Behrens, Edward

AU - Teachey, David T.

N1 - Funding Information: This work was supported by the Immune Dysregulation Frontier Program at the Children's Hospital of Philadelphia. This publication was made possible by an NHLBI-funded postdoctoral fellowship to MPT (T32 HL007150). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NHLBI or NIH.

PY - 2021/7

Y1 - 2021/7

UR - http://www.scopus.com/inward/record.url?scp=85102875640&partnerID=8YFLogxK

U2 - 10.1002/pbc.29026

DO - 10.1002/pbc.29026

M3 - Letter

C2 - 33754483

AN - SCOPUS:85102875640

SN - 1545-5009

VL - 68

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 7

M1 - e29026

ER -